▎WuXiEdited by Kant Content Team

TRIMTECH Therapeutics Announces Completion of $31 Million (£25 Million) Seed FinancingThis financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors' Dementia Discovery Fund (DDF), with participation from M Ventures and Pfizer Ventures.Other investors include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.

TRIMTECH Therapeutics is leveraging the unique properties of the E3 ubiquitin ligase TRIM21 toTRIMTACDevelopment of drugs in the form of degradable molecules.This drug aims to selectively and effectively degrade protein aggregates associated with various diseases, for which current protein degradation therapies often struggle to achieve significant effects, thereby offering new hope to patients with limited treatment options.

▲TRIMTAC Degrader Mechanism of Action (Image Source:TRIMTECH Therapeutics Official Website）

This investment will support the further development of the company's pipeline.TRIMTECHPipeline includes its polymer selectivityTRIMTAC Degrader, which is a potent agent capable of crossing the blood-brain barriermolecules, developing drugs for the treatment of severe neurodegenerative and inflammatory diseases, including Alzheimer's disease and Huntington's disease.

The company was co-founded by CIC and DDF, along with their resident entrepreneur Dr. Damian Crowther, academic co-founder Dr. Leo James of the MRC Laboratory of Molecular Biology, and Dr. Will McEwan of the UK Dementia Research Institute at the University of Cambridge.

‍

▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases. Retrieved March 5, 2025 from https://www.businesswire.com/news/home/20250305069531/en/TRIMTECH-Therapeutics-raises-31M-seed-funding-to-advance-targeted-protein-degradation-pipeline-for-treatment-of-neurodegenerative-diseases

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.